Skip to main content

AS/Spondyloarthritis

SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

Dec 01, 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in

Read Article
ICYMI: Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311.https://t.co/XEJMyvKDnx

Dr. John Cush @RheumNow( View Tweet )

Nov 27, 2021
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Nov 24, 2021

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311.https://t.co/6zARkjsoCg

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021
Spondyloarthritis Panel Discussion- #ACR21 Meeting https://t.co/tNckQa4mCK https://t.co/xgiKDXjtvA
Dr. John Cush @RheumNow( View Tweet )
Nov 23, 2021
ICYMI: Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.https://t.co/aCK1RRvTaW https://t.co/X1TlY88Jng
Dr. John Cush @RheumNow( View Tweet )
Nov 21, 2021
Best of SpA Abstracts Day 2: Dr. Robert Chao ( @doctorRBC) shares the best of SpA Abstracts from Day 2 of #ACR21.https://t.co/8oZipxMLCm https://t.co/jAifqBRgVc
Dr. John Cush @RheumNow( View Tweet )
Nov 18, 2021
Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.https://t.co/mOutSekQkJ https://t.co/JG18q9PsdD
Dr. John Cush @RheumNow( View Tweet )
Nov 15, 2021
ICYMI: New Insights into Uveitis in Spondyloarthritis There have been some updates on uveitis in SpA at #ACR21 shared by Dr. Antoni Chan ( @synovialjoints).https://t.co/lyKt8p5s4o https://t.co/A9tRmD4mBJ https://t.co/TZPThjrazR
Dr. John Cush @RheumNow( View Tweet )
Nov 14, 2021
ICYMI:Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS) Dr. Sheila Reyes(@RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.https://t.co/5kOv5BUU4P https://t.co/lKuXC0mLRt
Dr. John Cush @RheumNow( View Tweet )
Nov 13, 2021
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Radiographic Progression in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0907 and #0897 presented at the #ACR21 annual meeting.https://t.co/9hStWrfPOW https://t.co/XkgDjXE7Aq
Dr. John Cush @RheumNow( View Tweet )
Nov 12, 2021
Spondyloarthritis Roundtable Rehash of #ACR21 New therapies, delay in diagnosis, artificial intelligence in reading radiographs and MRIs, and more. Panelists includes Dr. Alexis Ogdie-Beatty, Dr. Jose Scher, Dr. Jack Cush and Dr. Christopher Ritchlin.https://t.co/K0pbddzLAF https://t.co/fS6wBNWOdJ
Dr. John Cush @RheumNow( View Tweet )
Nov 12, 2021
Predictors to Flare in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstracts #0929 and #0916 presented at the #ACR21 annual meeting.https://t.co/C0NLSTzlW9 https://t.co/3BiW2L6BJu
Dr. John Cush @RheumNow( View Tweet )
Nov 11, 2021
Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costshttps://t.co/Id658ocDVf#ACR21 Abst1777 @RheumNow

Pedro Castillo @_Castillo_Pedro( View Tweet )

Nov 09, 2021
AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently ⭐️🔽 clinic workload and better disease activity stratification Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting.https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

Nov 09, 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?



The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of

Read Article
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx
Nov 09, 2021
Should we be measuring drug levels in pts taking infliximab? ⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO) #ACR21 Abs#1946 #ACRBest @RheumNow https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Machine learning algorithm demonstrated high level of accuracy (88%) and precision (0.95) in diagnosing potential cases of axSpA ⭐️Is there a role for ML to facilitate faster rheum eval for suspicious axSpA cases? Abs#1922 #ACR21 @RheumNow https://t.co/tAPfROPICU https://t.co/HJD37B9jZw
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Retrospective cohort study FORWARD databank : ⭐️ 🔼opioid use was associated with higher HAQ-DI and BASDAI scores among patients with PsA or AS Annualized avg opioid use and costs 🔼with 🔼HAQ-DI and BASDAI scores for patients in both cohorts Abst#1117 #ACRBest @RheumNow https://t.co/KB9QUITbAe
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
×